12/26/2023 0 Comments Endo pharma things to look forThat misuse also contributed to outbreaks of infectious diseases including HIV and Hepatitis C. Local governments suing the company have demanded roughly $2.4 billion in damages.Įndo ended sales of Opana ER in 2017 after the Food & Drug Administration found it was often abused by people who crushed, dissolved and injected the medication. Almost all our crime is driven by drugs," he told NPR. "It's overdose deaths, it's people losing their jobs, losing their dignity. It has really ripped at the fabric of our community," said Barry Staubus, district attorney in Sullivan County Tennessee. They claim Endo's opioid medication Opana ER was marketed aggressively in the state without proper safeguards, contributing to high rates of addiction and death. Stranch's legal team filed a series of complaints with the court about Endo's conduct in the case, which led to the judge's order.Ī controversial opioid, a devastating epidemicĪt issue is a lawsuit filed in 2017 by county prosecutors and other local government officials in eastern Tennessee. " lawyers crossed the line and worked with the company to subvert the court's orders and then made false statements to the court about it," he said. In a statement emailed to NPR the company said it will appeal the judgement.īut Gerard Stranch, one of the attorneys suing the drugmaker on behalf of local governments in Tennessee, said Endo and its lawyers "conspired to hide the truth" over a period of years as the fact-finding phase of the trial proceeded. Moody in a judgment issued on April 6.Įndo denies wrongdoing. "It appears to the court that Endo and its attorneys, after delaying trial, have resorted to trying to improperly corrupt the record," wrote Chancellor E.G. The judge presiding over the civil trial also concluded the drugmaker and its attorneys made at least a dozen false statements during the pretrial fact-finding process. GVK BIO’s diverse portfolio of more than 200 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life science companies and leading academic institutions.A state judge in Tennessee ruled the drug company Endo Pharmaceuticals is liable for harm caused by their opioid drug, Opana ER.Ī state court in Tennessee has punished Endo Pharmaceuticals for improperly withholding a vast trove of documents relating to the sale and marketing of its opioid medication Opana ER. GVK BIO’s discovery services consist of Chemistry, Biology and Informatics the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. GVK Biosciences (GVK BIO, is Asia’s leading Discovery Research and Development organization. GVK Biosciences develops these assets to a stage of demonstrated value and then looks to partner and co-develop them with life science companies. This early stage asset portfolio is focused around Pain and Inflammation. GVK Biosciences, through its internal expertise in computational chemistry, discovery biology and medicinal chemistry, is building a portfolio of discovery project assets for potential early stage partnering. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients”.ĮDA TM (Early Discovery Assets) A new discovery offering from GVK BIO Sandeep Gupta, Endo’s Senior Vice President of Drug Discovery and Early Development stated “We are pleased to initiate this discovery collaboration with GVK BIO. This collaboration also confirms the value of our differentiated EDA TM concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”ĭr. Manni Kantipudi, CEO of GVK BIO commented, “We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA TM). Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein. GVK Biosciences (GVK BIO), Asia’s leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |